HIV/AIDS Topics amfAR Announces New Round of HIV Cure Research Grants
- Details
- Category: Search for a Cure
- Published on Thursday, 09 June 2016 00:00
- Written by amfAR
This month amfAR, the Foundation for AIDS Research, announced that it has granted 7 awards for research on HIV persistence, the understanding of which could lead to new approaches to an HIV cure -- part of the organization's Countdown to a Cure for AIDS initiative.
UNAIDS 90-90-90 Targets Could Prevent 2.5 Million HIV Deaths in South Africa
- Details
- Category: HIV Treatment
- Published on Thursday, 09 June 2016 00:00
- Written by Liz Highleyman
Achieving the UNAIDS 90-90-90 targets for getting more people with HIV tested and on effective treatment in South Africa would cost nearly 16 billion dollars over 10 years, but could avert more than 2 million new HIV infections and prevent 2.5 million deaths, according to a mathematical model analysis published in the May 31 online edition of Annals on Internal Medicine.
Genvoya TAF Regimen Works Well with Improved Bone and Kidney Safety at 96 Weeks
- Details
- Category: Approved HIV Drugs
- Published on Tuesday, 03 May 2016 00:00
- Written by Liz Highleyman
The Genvoya single-tablet regimen containing tenofovir alafenamide (TAF) suppressed HIV as well as a similar coformulation containing the older tenofovir disoproxil fumarate (TDF), but demonstrated better bone and kidney tolerability after 2 years of treatment, according to a report in the May 1 edition of the Journal of Acquired Immune Deficiency Syndromes.
June 5 Marks 35 Years Since First Report of AIDS
- Details
- Category: HIV Treatment
- Published on Friday, 03 June 2016 00:00
- Written by Liz Highleyman
Sunday, June 5th marks the 35th anniversary of the first report of what would come to be known as AIDS. The past 3 decades have included remarkable progress in the field -- including highly effective antiretroviral therapy and a pill that can prevent HIV infection -- but much remains to be done to make these advances available to all who need them.
Gene Therapy Snips HIV Out of Infected Cells and Makes Uninfected Cells Resistant
- Details
- Category: Search for a Cure
- Published on Sunday, 10 April 2016 00:00
- Written by Gus Cairns
For the first time, researchers have used a gene-editing technique related to one already used to produce cells resistant to HIV infection to target HIV-infected cells. They have managed to remove HIV genes completely from infected cells, as shown by reductions in the cells' overall rate of HIV production. In cells not already infected, the therapy has itself become part of their genome, producing cells that are resistant to infection for a prolonged period, according to a report in a recent edition of Nature Scientific Reports.
Model Suggests There Are Fewer People with HIV in U.S. and More on Treatment
- Details
- Category: Cascade of Care
- Published on Sunday, 08 May 2016 00:00
- Written by Gus Cairns
A study comparing recorded diagnoses of HIV with subsequent records of viral load and CD4 T-cell tests suggests that the number of people living with HIV in the U.S. could have been overestimated by as much as 45% -- and the proportion who are on antiretroviral therapy (ART) with undetectable viral loads could have been underestimated by as much as 50%. There could be as few as 820,000 people with HIV in the U.S. compared with the normally accepted figure of 1.2 million -- and up to 55% of those could be on ART and virally suppressed, compared with the most commonly quoted figure of 30%.
FDA Approves Descovy TAF Combination Pill for HIV Treatment, Not Yet for PrEP
- Details
- Category: Experimental HIV Drugs
- Published on Wednesday, 06 April 2016 00:00
- Written by Liz Highleyman
The U.S. Food and Drug Administration (FDA) this week approved Gilead Sciences' Descovy, a new combination pill containing tenofovir alafenamide (TAF), which is easier on the kidneys and bones than the older tenfovir disiproxil fumarate (TDF) version. The new coformulation is similar to Truvada, but it has been approved only for use as a component of HIV treatment, not for pre-exposure prophylaxis or PrEP.
More Articles...
- CROI 2016: Long-Acting MK-8591 Could Be Future Option for HIV Treatment and Prevention
- CROI 2016: VRC01 Antibody Delays But Does Not Prevent HIV Rebound After ART Interruption
- Johns Hopkins Team Performs Pioneering HIV+ to HIV+ Liver and Kidney Transplants
- CROI 2016: Dose-Finding Trials of Antibody-Based Drugs for HIV Prevention To Start Soon
- CROI 2016: Personalized Counseling Improves Rate of Entry into HIV Care
Web Design and Development by